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Abstract
Dengue virus (DENV) is the most prevalent arbovirus leading to an estimated 100 million
symptomatic dengue infections every year. DENV can cause a spectrum of clinical manifes-
tations, ranging from mild dengue fever (DF) to more life threatening forms such as dengue
hemorrhagic fever (DHF). The clinical symptoms of DHF become evident typically at the crit-
ical phase of infection (5–7 days after onset of fever), yet the mechanisms that trigger transi-
tion from DF to DHF are not well understood. We performed a mass spectrometry-based
metabolomic profiling of sera from adult DF and DHF patients at the critical and recovery
phases of infection. There were 29 differentially expressed metabolites identified between
DF and DHF at the critical phase. These include bile acids, purines, acylcarnitines, phos-
pholipids, and amino acids. Bile acids were observed up to 5 fold higher levels among DHF
compared to DF patients and were significantly correlated to the higher levels of aspartate
transaminase (AST) and alanine transaminase (ALT), suggestive of liver injury among DHF.
Uric acid, the most abundant antioxidant in the blood, was observed to be 1.5 fold lower
among DHF compared to DF patients. This could result in decreased capacity of endoge-
nous antioxidant defense and elevated oxidative stress among DHF patients. In the recov-
ery phase, the levels of eight metabolites were still significantly higher or lower among DHF
patients, including chenodeoxyglycocholic acid, one of the bile acids observed at the critical
phase. This indicates potential prolonged adverse impact on the liver due to DENV infection
in DHF patients. Our study identified altered metabolic pathways linked to DHF in the critical
and recovery phases of dengue infection and provided insights into the different host and
DENV interactions between DF and DHF. The results advance our understanding on the
mechanisms of DHF pathogenesis, alluding to possible novel therapeutic targets to dengue
management.
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Author summary
Dengue is a re-emerging disease caused by dengue viruses (DENV) and half of the world’s
population is now at risk of dengue infection. DENV can cause a spectrum of clinical
manifestations ranging from mild dengue fever (DF) to the potentially lethal dengue hem-
orrhagic fever (DHF). The molecular mechanisms that trigger transition from DF to DHF
are not well understood. To gain insights on the mechanisms of DHF pathogenesis, we
performed metabolomic profiling of sera from adult DF and DHF patients at the critical
phase of infection (5–7 days after onset of fever), the time point when the clinical symp-
toms of DHF become more evident. 29 differentially expressed metabolites between DF
and DHF were identified, allowing us to discover a variety of metabolite pathways linked
to DHF. They include bile acid biosynthesis, fatty acid β-oxidation, purine and pyrimidine
metabolism, phospholipid catabolism, tryptophan and phenylalanine metabolism, and so
on. The results advance our understanding on the mechanisms of DHF pathogenesis, and
certain altered pathways being harnessed as therapeutic targets to alleviate DHF. These
differentially expressed metabolites have the potential as biomarkers for disease monitor-
ing and evaluation of therapeutic interventions.
Introduction
Dengue is a re-emerging disease caused by four closely related serotypes of dengue viruses
(DENV) and it is endemic in the tropical and sub-tropical regions of the world. An estimated
100 million symptomatic dengue infections occur annually, with over half of the world’s popu-
lation living at the risk of infection [1]. Infection with DENV can cause a spectrum of clinical
manifestations ranging from mild dengue fever (DF) to the potentially lethal dengue hemor-
rhagic fever (DHF) and dengue shock syndrome (DSS), which are characterized by abnormal
hemostasis, vascular leakage and liver damage [2]. As yet, there is no specific treatment for
dengue and the management of DHF patients is primarily supportive. Furthermore, the lack
of an appropriate animal model poses great challenges in the study of dengue pathogenesis.
Dengue is a dynamic disease. After the incubation period, the illness begins abruptly and is
followed by the three phases—febrile (day 0–4 post onset of fever), critical (day 5–7 post onset
of fever) and recovery (day 21–28 post onset of fever). DF patients would recover uneventfully
after 5–7 days of acute illness, but for DHF patients, the initial febrile period is followed by a
rapid onset of vascular leakage, thrombocytopenia and hemorrhage at the critical phase. The
continual loss of intravascular volume from plasma leakage can rapidly lead to hypotension
and circulatory failure in DHF patients, which can result in death. The pathological difference
between DF and DHF suggest differential virus-host interaction in the susceptibility to the dis-
ease, and both viral and host immune factors are likely involved. Although numerous efforts
have been made in the last decade [3–6], the mechanisms that trigger transition from mild DF
to more life threatening DHF at the critical phase are not fully understood, hampering the
design of effective treatments for DHF.
Metabolomics is a rapidly emerging field in systems biology that refers to the global investi-
gation of metabolite pool in biological systems in response to biological stimuli or perturba-
tions [7]. Metabolites are the end products of cellular regulatory processes and form a direct
link between molecular changes and phenotypes, and by providing a snapshot of an organ-
ism’s metabolic status, metabolomics holds the promise of finding metabolites or metabolic
pathways related to disease processes [8,9]. It has been applied to infectious diseases to study
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host-pathogen interactions, including DENV infections [10–13]. In our previous study, we
investigated serum metabolome difference between adult DF and DHF patients enrolled from
a prospective dengue study at early febrile phase of DENV infection and found potential
marker metabolite to predict DHF at early phase of the infection [14]. In the present study,
metabolomics investigation was conducted on the same patient cohort at both the critical
phase and recovery phases, with an aim to study the potential mechanisms that may contribute
to the transition from DF to DHF at the critical phase of DENV infection. Interestingly, the
majority of identified differentially expressed metabolites between DF and DHF in the febrile
phase were different from those identified in the critical phase, showing that metabolomics
study could capture the distinct molecular changes in DF and DHF patients at different phases
of DENV infection. In the recovery phase, the levels of a few metabolites were still significantly
altered in DHF patients, indicating prolonged effects of DENV infection on DHF patients.
Our results identified metabolic pathways linked to dengue progression and provided insights
on the mechanisms of DHF pathogenesis.
Methods
Ethics statement
Enrollment of all eligible individuals was based on written informed consent and the collected
samples were anonymized. The protocols were approved by the Domain Specific Review
Board of the National Healthcare Group, Singapore (DSRB/E/2009/432).
Patient enrollment
The details of patient recruitment, sample collection and the study protocols of the study have
been described earlier [14]. Briefly, the study cohort of dengue patients were recruited from
the Prospective Adult Dengue Study (PADS), which is a cohort study of acute febrile adults at
a tertiary care center, Communicable Diseases Center, Tan Tock Seng Hospital, Singapore.
Adult patients ( 18 years) presenting with acute onset of fever ( 37.5˚C) without rhinitis or
other clinical alternatives were included in the study (Febrile stage, < 96 hours post onset of
fever; Critical, Day 5–7, Convalescence, Day 21–28). Venous blood samples were collected, ali-
quoted and frozen at -80˚C for hematological, virological and serological analysis. The study
design, hypotheses, patient characteristics, assay methods, statistical methods and modeling
methods were reported as per REMARK which is important for generalizability [15]. DF and
DHF patients were classified according to the WHO 1997 and 2009 dengue guidelines [2,16].
To fulfill the case definition of DHF, all four of the following criteria must be present, namely:
fever or history of fever, hemorrhagic tendencies, thrombocytopenia and evidence of plasma
leakage [16]. Hematoconcentration was determined by the hematological analyzer and
expressed as % of the volume of whole blood that was made up of red blood cells. Hematocrit
increase of over 20% of the values at convalescence phase is considered a common clinical
index of plasma leakage and DHF diagnosis. The PADS cohort comprised of both DF and
DHF patients recruited at different phases of dengue infection and DENV2 is the predominant
DENV type. Based on the anti-DENV IgG and IgM seropositivity or seronegativitiy, immune
status of the patients was determined. Anti-DENV IgM seropositivity and IgG seronegativity
indicated that 40–52% of DF and 22–41% of DHF are primary cases, and the remaining are
secondary cases. 12–16% DF patients and 59–76% DHF patients had platelets <50×103/μL at
any point as determined during their daily routine total blood count.
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Hematological, serological and virological analysis
A detailed hematological and virological analysis was performed and included white blood cell
count (WBC), red blood cell count (RBC), blood hemoglobin (HGB), hematocrit (HCT),
mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular
hemoglobin concentration (MCHC), platelet count (PLT), lymphocyte percentage (LYMPH
%), lymphocyte count (LYMPH), mixed cell count (MXD), neutrophil percentage (NEUT%),
neutrophil count (NEUT), red blood cell distribution width-coefficient of variation
(RDW-CV), and quantitation of peripheral viral titers using reverse transcriptase-polymerase
chain reaction (RT-PCR) crossover values (Ct). Dengue viral infection was confirmed by
RT-PCR [17], or NS1 detection by Dengue NS1 Ag Strip (Bio-Rad, Marnes-la-Coquette,
France) at the Environmental Health Institute, Singapore, or typing by virus isolation and
immunofluorescence using DENV type-specific monoclonal antibodies (ATCC: HB46-49).
Dengue-immune status (primary or secondary DENV infection) was based on Dengue IgG
levels in the acute sera, using a commercially obtained ELISA (PanBio, Brisbane, Australia)
according to the manufacturer’s protocol.
Sample preparation
A volume of 50 μL from each serum sample was thawed at 4˚C and serum proteins were pre-
cipitated with 200 mL ice-cold methanol, which contained 10 mg/mL 9-fluorenylmethoxycar-
bonyl-glycine as an internal standard. After vortexing, the mixture was centrifuged at 16,000
rpm for 10 minutes at 4˚C and the supernatant was collected and evaporated to dryness in a
vacuum evaporator. The dry extracts were then redissolved in 200 μL of 98:2 water/methanol
for liquid chromatography-mass spectrometry (LC-MS) analysis. Quality control (QC) sam-
ples were prepared by mixing equal amounts of serum samples from all the samples and pro-
cessed as per other samples. The QC sample was run after each 8 samples to monitor the
stability of the system and all samples were randomized.
Metabolomics analysis by LC-MS
Metabolomics analysis was performed as previously described [14]. Briefly, the supernatant
fraction from sample preparation step was analyzed using Agilent 1290 ultrahigh pressure
liquid chromatography system (Waldbronn, Germany) equipped with a 6550 QTOF mass
detector managed by a MassHunter workstation. The column used for the separation was an
Agilent rapid resolution HT Zorbax SB-C18 (2.1×100 mm, 1.8 mm; Agilent Technologies,
Santa Clara, CA, USA). The oven temperature was set at 45˚C. The gradient elution involved
a mobile phase consisting of (A) 0.1% formic acid in water and (B) 0.1% formic acid in
methanol. The initial condition was set at 5% B. A 7 min linear gradient to 70% B was
applied, followed by a 12 min gradient to 100% B which was held for 3 min, then returned to
starting conditions over 0.1 min. Flow rate was set at 0.4 ml/min, and 5 μL of samples was
injected. The electrospray ionization mass spectra were acquired in both positive and nega-
tive ion mode. Mass data were collected between m/z 100 and 1000 at a rate of two scans per
second. The ion spray voltage was set at 4,000 V, and the heated capillary temperature was
maintained at 350˚C. The drying gas and nebulizer nitrogen gas flow rates were 12.0 L/min
and 50 psi, respectively. Two reference masses were continuously infused to the system to
allow constant mass correction during the run: m/z 121.0509 (C5H4N4) and m/z 922.0098
(C18H18O6N3P3F24).
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Data analysis
Raw spectrometric data in untargeted metabolomics were analyzed by MassHunter Qualita-
tive Analysis software (Agilent Technologies, US) and the molecular features characterized
by retention time (RT), chromatographic peak intensity and accurate mass, were obtained
by using the Molecular Feature Extractor algorithm. The features were then analyzed by
MassHunter Mass Profiler Professional software (Agilent Technologies, US). Only features
with an intensity  20,000 counts (approximately three times the limit of detection of our
LC-MS instrument), and found in at least 80% of the samples at the same sampling time
point signal were kept for further processing. Next, a tolerance window of 0.15 min and 2
mDa was used for alignment of RT and m/z values, and the data normalized to spiked
9-fluorenylmethoxycarbonyl-glycine internal standard. Raw spectrometric data in targeted
metabolomics were processed using MassHunter Workstation Quantitative Analysis soft-
ware (Agilent Technologies, US).
For statistical analysis, nonparametric Mann–Whitney Test with Benjamini-Hochberg
Multiple Testing Correction was employed, and statistical significance was set at p<0.05.
For multivariate data analysis using principle component analysis (PCA) or Orthogonal pro-
jections to latent structures discriminant analysis (OPLS-DA), data were normalized by
median-centering and dividing by standard deviation. PCA and OPLS-DA were performed
using the software package SIMCA-P 13.0 version (Umetrics AB, Umea, Sweden). Metabo-
lites with Variable Importance in the Projection (VIP) values>1 were considered to be influ-
ential for the separation of samples in OPLS-DA analysis. In addition, the fold change
(FC) analysis was also performed to further filter the features and only those features with
FC > 1.5 were selected as potential significantly altered metabolites. The hierarchical cluster
analysis (HCA), a cluster analysis method which seeks to build a hierarchy of clusters, was
performed using MeV4.0.
Compound identification
The structure identification of the differentially expressed metabolites was based on our pub-
lished work [18]. Briefly, the elemental compositions of the metabolites were first calculated
based on the exact mass, the nitrogen rule and the isotope pattern by Masshunter software
from Agilent. Then, the elemental composition and exact mass were used for open source
database searching with a cutoff value of 10 parts per million (ppm), including LIPIDMAPS
(http://www.lipidmaps.org/), HMDB (http://www.hmdb.ca/), METLIN (http://metlin.scripps.
edu/) and MassBank (http://www.massbank.jp/). Next, MS/MS experiments were performed
to obtain structural information via the interpretation of the fragmentation pattern of the
metabolite. The MS/MS spectra of possible metabolite candidates in the databases were also
searched and compared. Finally, the metabolites were confirmed by comparison with the stan-
dards where commercially available. The metabolites are listed according to the minimum
reporting standards for chemical analysis in metabolomics recommended by Metabolomics
Standard Initiative (MSI) [19,20]. Briefly, a four-level system ranging from Level 1 (identified
metabolites, e.g. based upon the co-characterization with reference standards) via Levels 2
(putatively annotated compounds, e.g. without chemical reference standards, based upon
physicochemical properties and/or spectral similarity with public/commercial spectral librar-
ies) and 3 (putatively characterized compound classes, e.g. based upon characteristic physico-
chemical properties of a chemical class of compounds, or be spectral similarity to known
compounds of a chemical class) to Level 4 (unidentified or unclassified metabolites which can
still be differentiated based on spectrum data). For metabolic pathway analysis, MetaboAnalyst
was used to identify relevant pathways [21].
Metabolomics study of severe dengue
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Results
Serum metabolic profiles of DF and DHF patients at critical and recovery
phase
We characterized serum metabolome changes between DF (n = 25) and DHF (n = 27) patients
at both the critical phase and recovery phase of infection using LC-MS. We first evaluated the
stability and reproducibility of the LC-MS method by performing PCA on all the samples
including the 6 QC samples [22]. As shown in S1 and S2 Figs, the QC samples are clustered in
PCA scores plots of sera (S1 and S2 Figs), indicating good stability and reproducibility of the
chromatographic separation of the metabolomics analysis.
Identification of significantly altered metabolites in DHF patients at
critical and recovery phase
In the critical phase, a total of 29 MSI Levels 1 and 2 metabolites, were significantly expressed
between DHF and DF patients, were identified. HCA could successively merge similar groups
of objects and the objects are joined together in a hierarchical fashion from the closest, that is
most similar, to the furthest apart, that is the most different. HCA based on the metabolome
profile could segregate DHF and DF patients in the critical phase (Fig 1), where all but two
DHF patients were classified together with DF. These differentially expressed metabolites
belonged to classes such as bile acid, acylcarnitine, phosphatidylcholine (PC), lysophosphati-
dylcholine (LysoPC), amino acid and derivative, dipeptide, purine and pyrimidine (Table 1).
Compared to DF patients, 10 of the 29 differentially expressed metabolites were increased in
DHF patients. Among them, the levels of the bile acids showed about 5 times higher in DHF
patients than in DF patients (Fig 2). Furthermore, these bile acids demonstrated positive corre-
lations to AST and ALT levels, indicating they may be associated with liver dysfunction in
DHF (Fig 3). The other 19 differentially expressed metabolites, including purines and pyrimi-
dines, most of the acylcarnitines and lipids, were decreased in DHF patients. In the recovery
phase, 8 altered MSI Levels 1 and 2 metabolites between DF and DHF patients were structur-
ally identified including bile acid, phospholipids, amino acid, dipeptide, and fatty acid
(Table 2). Among these differentially expressed metabolites, the level of the bile acid, cheno-
deoxyglycocholic acid, was still about 3 times higher in DHF patients than in DF patients, indi-
cating prolonged effects of DENV infection on DHF patients (Fig 4).
To assess their potential in differentiating DF and DHF, Receiver Operating Curve analyses
were performed for the differentially expressed metabolites in the critical phase. Several metab-
olites showed good performing Area Under Curve (AUC), including serotonin (AUC = 0.85,
95% C.I. 0.75–0.95, p<0.0001), uridine (AUC = 0.81, 95% C.I. 0.68–0.93, p = 0.0002), glycour-
sodeoxycholic acid (AUC = 0.77, 95% C.I. 0.65–0.90, p = 0.0007), uric acid (AUC = 0.76, 95%
C.I. 0.63–0.89, p = 0.001) (S3 Fig).
We have previously identified more than 20 differentially expressed metabolites between
DF and DHF in the early febrile phase of dengue. Surprisingly, a distinct set of differentially
expressed metabolites between DF and DHF were found in critical phase as compared to the
early febrile phase. There are only two common metabolites between these two phases and
they are serotonin and a dipeptide.—We have shown previously through a stable-isotope dilu-
tion mass spectrometry method that serotonin was significantly changed among DHF patients
as compared to DF patients in the febrile phase, and serotonin remained significantly altered
among the DHF patients in the critical phase. This finding demonstrated the high reliability
and confidence of our methodologies and results in our previous and current untargeted anal-
ysis approach. In addition, for the three bile acids which were significantly increased among
Metabolomics study of severe dengue
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DHF patients as compared to DF patients in the critical phase, their levels was also higher
among DHF patients in the febrile phase, but it was not statistically significant. On the other
hand, a few fatty acid amides were significantly lower among DHF patients as compared to DF
patients in the febrile phase, and their levels became similar between DF and DHF patients in
the critical phase.
Fig 1. Hierarchical heatmap clustering with identified differentially expressed metabolites segregates critical
phase dengue fever (DF) and dengue hemorrhagic fever (DHF) patients. Each column shows ion intensity for a
specific metabolite after mean centering and unit variance scaling of the data. Each row shows the serum metabolic
profiles of DF and DHF patients.
https://doi.org/10.1371/journal.pntd.0006217.g001
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We used MetaboAnalyst, a pathway analysis tool, to determine the underlying biochemical
pathways revealed by the identified metabolites. The perturbed metabolic pathways in DHF in
the critical phase included bile acid biosynthesis, fatty acid β-oxidation, purine and pyrimidine
metabolism, phospholipid catabolism, tryptophan and phenylalanine metabolism. (S4 Fig) In
the recovery phase, the bile acid biosynthesis and phospholipid catabolism pathways were still
altered, while other metabolic pathways were no longer disturbed in DHF patients (S5 Fig).
Discussion
Dengue is a very dynamic disease, and the symptoms of DHF usually do not occur until the
critical phase of infection. The critical phase is known as the danger period of dengue because
a small proportion of patients may undergo sudden deterioration over 24–48 h. If the patient
recovers, there are no sequelae in uncomplicated dengue, symptoms resolve and clinical
parameters normalize. The mechanisms that contribute to the transition from DF to DHF are
not well understood, although the pathological differences between DF and DHF suggest dif-
ferential virus-host interactions in the susceptibility to the disease.
Table 1. Identified differentially expressed metabolites between dengue fever (DF) and dengue hemorrhagic fever (DHF) patients in the critical phase of infection.
HMDB Accurate mass Metabolite Chemical formula p value Fold change (DHF/DF) Pathway
HMDB00289 168.0288 Uric acid C5H4N4O3 0.0005 0.66 Purine metabolism
HMDB00157 136.0385 Hypoxanthine C5H4N4O 0.01 0.52 Purine metabolism
HMDB00296 244.0695 Uridine C9H12N2O6 0.0003 0.70 Pyrimidine metabolism
HMDB06898 449.3149 Chenodeoxyglycocholic acid C26H43NO5 0.039 4.63 Bile acid biosynthesis
HMDB00708 449.3142 Glycoursodeoxycholic acid C26H43NO5 0.0177 5.96 Bile acid biosynthesis
HMDB00138 465.3084 Glycocholic acid C26H43NO6 0.0357 6.23 Bile acid biosynthesis
HMDB00824 217.1318 Propionylcarnitine C10H19NO4 0.0073 1.56 fatty acid β-oxidation
HMDB13324 285.194 2-Octenoylcarnitine C15H27NO4 0.021 0.70 fatty acid β-oxidation
HMDB61640 387.2984 3-hydroxytetradecanoyl carnitine C21H41NO5 0.023 0.70 fatty acid β-oxidation
HMDB61634 303.2045 3-hydroxyoctanoyl carnitine C15H29NO5 0.0007 0.55 fatty acid β-oxidation
HMDB06461 423.3348 Linoleyl carnitine C25H45NO4 0.045 0.71 fatty acid β-oxidation
HMDB00259 176.0928 Serotonin C10H12N2O 0.0001 0.42 Tryptophan metabolism
HMDB00671 205.0739 Indolelactic acid C11H11NO3 0.01 0.56 Tryptophan metabolism
HMDB00159 165.0795 L-Phenylalanine C9H11NO2 0.0019 1.59 phenylalanine metabolism
HMDB00714 179.0591 Hippuric acid C9H9NO3 0.0397 3.59 phenylalanine metabolism
HMDB28922 202.1318 Leucyl-Alanine C9H18N2O3 0.0047 0.63 Dipeptide
HMDB13302 312.1475 Phenylalanylphenylalanine C18H20N2O3 0.0374 0.50 Dipeptide
HMDB29036 208.0517 Serinyl-Cysteine C6H12N2O4S 0.03 0.70 Dipeptide
HMDB10386 519.3316 LysoPC(18:2) C26H50NO7P 0.0201 0.59 Glycerophospholipid
HMDB10382 495.3321 LysoPC(16:0) C24H50NO7P 0.0241 0.66 Glycerophospholipid
HMDB10384 523.3635 LysoPC(18:0) C26H54NO7P 0.045 0.64 Glycerophospholipid
HMDB11526 525.2855 LysoPE(22:6) C27H44NO7P 0.018 1.56 Glycerophospholipid
HMDB10404 567.3324 LysoPC(22:6 C30H50NO7P 0.025 1.45 Glycerophospholipid
HMDB08392 793.5985 PC(P38:4) C46H84NO7P 0.003 0.72 Glycerophospholipid
HMDB08020 811.6091 PC(38:3) C46H86NO8P 0.045 0.71 Glycerophospholipid
HMDB02183 328.2376 Docosahexaenoic acid C22H32O2 0.0457 0.58 fatty acid
HMDB00413 246.1467 3-Hydroxydodecanedioic acid C12H22O5 0.0402 0.54 Organic acid
HMDB01987 118.063 2-Hydroxy-3-methylbutyric acid C5H10O3 0.006 1.42 Organic acid
HMDB00267 129.0424 Pyroglutamic acid C5H7NO3 0.0379 1.51 glutathion metabolism
 Verified with authentic standards
https://doi.org/10.1371/journal.pntd.0006217.t001
Metabolomics study of severe dengue
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006217 January 24, 2018 8 / 15
In our previous study a systematic characterization of serum metabolome at early febrile
phase (< 96 hours post onset of fever) was reported from adult DF/DHF patients enrolled
from a prospective dengue study [14]. In the present study, metabolomics investigation was
conducted on the same patient cohort at the critical phase (day 5–7 post onset of fever) and
recovery phase (day 21–28 post onset of fever) to map the serum metabolome and identify
metabolic pathways linked to dengue progression. Interestingly, the majority of identified dif-
ferentially expressed metabolites between DF and DHF in the critical phase were different
from the ones identified in the early febrile phase, showing that metabolomics study could cap-
ture the specific molecular changes in DF/DHF patients at different phases of infection. In the
recovery phase, the levels of a number of lipids were still significantly altered in DHF patients,
indicating prolonged effects of DENV infection on DHF patients. Our results could help to
Fig 2. Box plots of representative differentially expressed metabolites between dengue fever (DF) and dengue hemorrhagic fever (DHF) patients
during critical phase. A. Chenodeoxyglycocholic acid B. Glycocholic acid C. Glycoursodeoxycholic acid D. Uric acid E. Hypoxanthine F. Uridine G.
3-Hydroxyoctanoyl carnitine H. 2-Octenoylcarnitine I. L-phenylalanine. Horizontal lines represent median value.  p<0.05,  p<0.01,  p<0.001, by
Mann-Whitney test. The statistical comparison was with DF levels.
https://doi.org/10.1371/journal.pntd.0006217.g002
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Fig 3. Pearson correlation analysis reveals correlation of bile acids with aspartate transaminase (AST) and alanine transaminase
(ALT) levels in the critical phase of infection.
https://doi.org/10.1371/journal.pntd.0006217.g003
Table 2. Identified differentially expressed metabolites between DF and DHF patients in the recovery phase of dengue infection.
HMDB Accurate mass Metabolite Chemical formula p value Fold change (DHF/DF) Pathway
HMDB06898 449.3141 Chenodeoxyglycocholic acid C26H43NO5 0.0095 2.96 Bile acid biosynthesis
HMDB00910 214.1932 Tridecanoic acid C13H26O2 0.006 0.73 fatty acid
HMDB13464 702.5675 SM(d34:1) C39H79N2O6P 0.0097 1.54 sphingolipid
HMDB08946 763.5152 PE(38:6) C43H74NO8P 0.0158 1.68 Glycerophospholipid
HMDB00593 785.5934 PC(36:2) C44H84NO8P 0.0006 1.78 Glycerophospholipid
HMDB00991 159.1259 DL-2-Aminooctanoic acid C8H17NO2 0.0438 0.70 amino acid
HMDB28757 246.1215 Aspartyl-Leucine C10H18N2O5 0.0183 1.70 Dipeptide
HMDB29118 280.1423 Tyrosyl-Valine C14H20N2O4 0.002 0.68 Dipeptide
https://doi.org/10.1371/journal.pntd.0006217.t002
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identify metabolic pathways linked to dengue progression and understand the mechanisms of
DHF pathogenesis.
We have previously found that the levels of bile acids are higher in DF patients than in
healthy controls at febrile and critical phases of infection [13]. In this study, we further showed
that DHF patients had even higher levels of bile acids than DF patients at both critical and
recovery phases of infection. Bile acids, which are formed in the liver as the end products of
cholesterol metabolism, can not only facilitate hepatobiliary secretion of endogenous metabo-
lites and nutrient absorption in the intestine, but also play important roles in regulating glu-
cose and lipid metabolism through bile acid receptors [23]. When present in abnormally high
levels, bile acids are highly toxic to cells, and impaired bile acid homeostasis could contribute
to the pathogenesis of liver and intestinal diseases [24]. Many studies have implicated that
DENV has adverse effect on liver functions in dengue patients and dengue infection is believed
to be an important cause of acute viral hepatitis in endemic countries [25,26]. The hepatocytes
and Kupffer cells in the liver could be the targets for DENV replication and a number of liver
hepatic histological changes have been observed in dengue patients [26–28]. Accumulated bile
Fig 4. Box plots of representative differentially expressed metabolites between dengue fever (DF) and dengue hemorrhagic fever (DHF) patients
during recovery phase. A. Chenodeoxyglycocholic acid B. PE (38:6) C. PC (36:2) D. SM (34:1). Horizontal lines represent median value.  p<0.05,
 p<0.01,  p<0.001, by Mann-Whitney test. The statistical comparison was with DF levels.
https://doi.org/10.1371/journal.pntd.0006217.g004
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acids in the hepatocytes could result in mitochondrial damage and may eventually lead to apo-
ptosis or necrosis [29]. It has been shown that DHF patients had a higher risk of developing
acute liver failure (p< 0.001) and liver pathology has been viewed as one of the hallmarks of
DHF [2, 30]. In the clinic, liver enlargement and elevated transaminases have been used as the
clinical features of hepatic histological changes in dengue patients [31], and we indeed found
in this study that AST and ALT levels were significantly higher in DHF than in DF. Put
together, elevated bile acids among DHF patients and their positive correlations to AST and
ALT levels indicated that these bile acids may play an important role in liver pathology in
DHF patients. Furthermore, a recent phase II clinical trial showed that INT-747, a potent ago-
nist of bile acid farnesoid X receptor, could improve histological activity and reduce fibrosis in
adult patients with non-alcoholic steatohepatitis [32], indicating bile acid receptors may be a
potential therapeutic target for liver disease management in DHF.
In this study, decreased uric acid was observed in DHF patients compared to DF patients at
the critical phase. Uric acid is an end product of purine catabolism, and numerous studies
have shown that uric acid is a major antioxidant in the blood and can help to protect against
free-radical oxidative damage [33,34]. It is reported that the total antioxidant capacity in the
blood was positively correlated with uric acid concentration, and low circulating levels of uric
acid have been associated with disease conditions with a significant redox imbalance due to
increased production of oxidant species and decreased capacity of endogenous antioxidant
defenses [35,36]. Indeed, increased ROS and NOS have been reported in DHF patients [37].
Furthermore, we have previously found higher levels of phenylalaninein DF patients than in
healthy controls. In this study, when compared to DF patients, a further increase of phenylala-
nine in DHF patients was observed. We have proposed that the accumulation of phenylalanine
was due to elevated oxidative stress status in dengue patients where superoxide and peroxyni-
trite increase oxidation of tetrahydrobiopterin (BH4), thereby depleting the available BH4
pool [38]. BH4 is a co-factor for phenylalanine (4)-hydroxylase (PHA), an enzyme required
for converting phenylalanine to tyrosine. Thus, higher level of phenylalanine also indicates
increased oxidative stress in DHF patients. Together, decreased uric acid could result in
impaired ability to scavenge the ROS and NOS in DHF patients. It had been shown that sys-
temic uric acid administration could increase serum antioxidant capacity in healthy volunteers
[39], which might be a potential intervention strategy of the condition of DHF.
In our previous studies, we have shown that anti-inflammatory responses played an impor-
tant role in modulating pro-inflammatory processes to prevent the development of pathologies
by excessive or prolonged inflammation in DF patients, and higher levels of Docosahexaenoic
acid (DHA) were found in DF patients than in healthy controls [13]. In current study, a
decrease of DHA in DHF patients was observed when compared to DF patients. DHA, an
omega-3 polyunsaturated fatty acid, is known for the anti-inflammatory activity by suppress-
ing the production of pro-inflammatory cytokines [40], and the lower level of DHA could indi-
cate impaired anti-inflammatory functions in DHF patients compared to DF patients. We
have also found earlier that the levels of many acylcarnitines, essential intermediates of fatty
acid β-oxidation, were higher in DF patients than in healthy controls, suggesting disturbed
energy metabolism in DF patients [13]. Interestingly, when compared to DF patients,
decreased levels of acylcarnitine were found in DHF patients in this study, indicating DHF
actually induced less disturbance in fatty acid β-oxidation than DF.
Voge et al had also conducted mass spectrometry-based serum metabolomics studies on
non-dengue (ND) controls, DF and DHF patients and identified 13 metabolites that statisti-
cally differentiate DHF, DF and ND groups, including amino acids, lipids and vitamins
[12]. Interestingly, most of the 13 differentially expressed metabolites were not found in our
current study. This is likely due to the different analytical platforms used in the two studies,
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hydrophilic interaction liquid chromatography versus RP liquid chromatography, leading to
different metabolite coverage. Nevertheless, both studies showed that metabolomics approach
could identify metabolites associated with distinct disease outcomes of dengue infection.
In summary, our study identified differentially expressed metabolites and the underlying
metabolic pathways linked to DHF in both the critical and recovery phases of dengue infec-
tion. These results provide insights into the mechanisms of DHF pathogenesis, and certain
altered pathways might serve as therapeutic targets to alleviate DHF.
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